


COVID-19: The Spearpoint for Rolling Out a “New Era” of High-Risk, Genetically Engineered Vaccines

[COVID-19: The Spearpoint for Rolling Out a “New Era” of High-Risk, Genetically Engineered Vaccines](#)

by the [Children’s Health Defense Team](#)

May 7, 2020



[Note: This article represents Part I of a two-part series examining COVID-19 vaccine technologies and their implications.]

For weeks, talking heads have been promoting the [liability-free](#) vaccine(s) that will save the world—so Bill Gates and Tony Fauci proclaim—from what Gates has now dubbed “Pandemic I.” As *Microsoft News* peddles self-congratulatory stories about the Gates Foundation’s reorientation of its priorities to devote “‘[total attention](#)’ to the pandemic,” Fauci—making the rounds of talk shows—pledges that a vaccine will make its debut in [January 2021](#). Not to be outdone, the White House has now unveiled “Operation Warp Speed”—a joint pharmaceutical-government-military effort aimed at “substantially [shrinking the development time](#) for a vaccine”—and President Trump promises one by the [end of the year](#).

Planet-wide COVID-19 vaccination—the overt objective that has all of these players salivating in anticipation—ignores a number of irrefutable obstacles. For one, the RNA virus being targeted, SARS-CoV-2, already “has mutated into [at least 30 different genetic variants](#).” The variants include 19 never seen before as well as “rare changes that scientists had never imagined could happen.” Knowledge about these mutations may prove useful to clinicians wanting to better tailor their COVID-19 [treatments](#), but the proliferation of mutations makes the chances of developing an effective vaccine immensely more uncertain.

Not to worry, say the entities funded by [Gates](#) (and also the [Pentagon](#)). Scientists working in the burgeoning field of synthetic biology are confident that they can “outdo” and outsmart [nature](#) using next-generation vaccine technologies such as [gene transfer](#) and [self-assembling nanoparticles](#)—along with invasive new vaccine delivery and record-keeping mechanisms such as smartphone-readable [quantum dot tattoos](#). Does it matter that the researchers who have been experimenting with these approaches have never been able to overcome “[nasty side effects](#)”? Apparently not. Aided and abetted by the generous Gates and military funding, high-fanfare COVID-19 vaccine planning is proceeding apace.

Researchers reiterated this point ... that for most emerging virus vaccines, the main obstacle is not the effectiveness of conventional approaches but the need for more rapid development and large-scale deployment.

Speed, not safety

From a manufacturing standpoint, vaccine makers—and particularly those making *viral* vaccines—have long chafed at the [limitations](#) of traditional vaccine technologies, which rely on processes that necessarily entail “a considerable [lag time](#) between antigen production and vaccine delivery.” Researchers reiterated this point again in 2018, writing in *Nature Reviews Drug Discovery* that “for most emerging virus vaccines, the main obstacle is not the effectiveness of conventional approaches but the need for [more rapid development and large-scale deployment](#).”

In the 1980s, manufacturers were elated when scientists developed new [genetic engineering techniques](#) (recombinant DNA technology) that—through the use of “expression systems” (bacteria, yeast, insect cells, mammalian cells or plants such as [tobacco](#))—made it possible to jumpstart vaccine production and produce so-called “subunit vaccines.” The hepatitis B vaccine was the first to employ this “[entirely new](#)” vaccine production approach, and a number of the COVID-19 vaccines currently [in the works](#) are deploying these techniques. However, a complicating factor of subunit vaccines is that they must be bundled with “immunopotentiating” [adjuvants](#) that tend to trigger an imbalanced immune response.

Desirous of streamlining vaccine technology still further and enabling vaccine stockpiles [in an even shorter time frame](#), researchers began tinkering in the mid-1990s with nucleic acid vaccines, which include DNA vaccines and messenger RNA (mRNA) vaccines. As a form of gene therapy, both represent a [significant departure](#) from classical vaccines. Whereas the latter introduce a vaccine antigen to produce an immune response, nucleic acid vaccines instead send the

body [instructions](#) to produce the antigen itself. As one researcher [explains](#), the nucleic acids “cause the cells to make pieces of the virus,” with the goal being that the immune system then “mounts a response to those pieces of the virus.”

Researchers quickly learned that both the DNA and mRNA vaccine options have serious downsides, and as a result, vaccines of this type have never been licensed. Nonetheless, almost one-fourth (20/83) of the vaccines [listed](#) by the World Health Organization as COVID-19 “candidate vaccines” as of April 23—including two of the leading contenders—are DNA (Inovio) or mRNA (Moderna) vaccines (see table).

DNA vaccines, by definition, come with the risk of integration of exogenous DNA into the host genome, which may cause severe mutagenesis and induced new diseases.

DNA vaccines

DNA vaccines are intended to penetrate all the way into a cell’s nucleus. According to one biotech scientist, “This is an incredibly difficult task given that our nuclei have evolved to prevent any [foreign DNA](#) from entering (Think viruses!).” Not surprisingly, then, when some DNA vaccines made it into clinical trials in the late 2000s, they were plagued by “[suboptimal potency](#).” Scientists then came up with the idea of solving this problem by augmenting vaccine delivery with “[electroporation](#)”—electric shocks applied to the vaccine site (using a “[smart device](#)”) to make cell membranes more permeable and force the DNA into the cells. The improvements in vaccine efficacy were significant enough that electroporation remains a key design feature of some COVID-19 vaccine candidates today, including the Moderna vaccine that is now speeding toward Phase 2 clinical trials.

A second aspect of DNA vaccines—their gene-altering properties—is even more troubling and remains unresolved. DNA vaccines, by definition, come with the risk of “[integration of exogenous DNA into the host genome](#),” which may cause severe

mutagenesis and induced new diseases.” Framed in more understandable terms, “disruption from DNA is like [inserting a foreign ingredient](#) in an existing recipe, which can change the resulting dish.” The permanent incorporation of synthetic genes [into the recipient’s DNA](#) essentially produces a genetically modified human being, with unknown long-term effects. Speaking of DNA gene therapy, one researcher has stated, “Genetic integrations using viral gene therapies . . . can have a devastating effect if the integration was [placed in the wrong spot](#) in [the] genome.” Discussing DNA vaccines specifically, the [Harvard College Global Health Review](#) elaborates:

Potential side effects could include chronic inflammation, because the vaccine continuously stimulates the immune system to produce antibodies. Other concerns include the possible integration of plasmid DNA into the body’s host genome, resulting in mutations, problems with DNA replication, triggering of autoimmune responses, and activation of cancer-causing genes.

mRNA vaccines

Because mRNA vaccines are “particularly suited to speedy development,” it is perhaps unsurprising that they are attracting attention as the “[coronavirus frontrunners](#).” mRNA vaccines can reportedly generate savings of “[months or years](#) to standardize and ramp up . . . mass production.” Making lemonade out of lemons, insiders casually state that “while no mRNA vaccine has ever been licensed, the threat of a pandemic is a [great incentive](#) to accelerate their progress.”

Companies are enamored of the mRNA approach despite observations that the large mRNA molecules are “[intrinsically unstable](#),” “prone to degradation” and may overactivate the immune system. On the plus side, from vaccine scientists’ standpoint, mRNA vaccines need only reach the [cell cytoplasm](#) rather than the nucleus—an apparently “simpler

technical challenge”—although the approach still demands “delivery technologies that can ensure stabilization of mRNA [under physiological conditions](#).” Formulations such as Moderna’s mRNA-1273 vaccine tackle these challenges by using “[chemical modifications](#) to stabilize the mRNA” and liquid nanoparticles to “package it into an injectable form.”

mRNA approaches seem to attract researchers with a highly mechanistic view of human beings. One such individual praises mRNA for its “inherent ‘[programmability](#),’” stating “Much like [a] computer [operating system], mRNA therapy can **reprogram** [one’s] body to produce its own therapies” [*emphasis in original*]. The CEO of Moderna describes mRNA approaches—which use “custom-built” strands of mRNA to “turn the body’s cells into ad hoc drug factories”—as being “like [software](#): You can just turn the crank and get a lot of products going into development.” Likewise, the journal *Nature* (commenting on mRNA technology from “a biotech and industrial perspective”) enthuses that the approach “allows rapid refinement with [almost limitless combinations](#) of derivatives.”

Vaccine researchers familiar with both DNA and mRNA vaccines like to play up mRNA vaccine safety, citing the fact that the vaccines do not have to penetrate the cell nucleus. However, with years of mRNA vaccine experimentation behind them, none of these researchers has yet achieved licensure. Why? One answer may be that in preclinical studies, mRNA vaccines have displayed an “intrinsic” [inflammatory component](#) that makes it difficult to establish an “acceptable risk/benefit profile.” mRNA enthusiasts admit that there is, as yet, an inadequate understanding of the [inflammation and autoimmune reactions](#) that may result. This raises many questions about what will happen if regulators grant the manufacturers of COVID-19 mRNA vaccines their wish for “a [fast-track process](#) to get mRNA vaccines to people sooner.”

Racing toward profits

The hijacking of nearly all economic, social, artistic and religious activity by SARS-CoV-2 is disturbing on many levels, not least because of what it reveals about the public's uncritical acceptance of official spin and its yearning for medical silver bullets. As a vaccine researcher at Sweden's Karolinska Institute has [stated](#):

When China quarantined an entire megacity in January, People said "only China can do that." Then we saw similarly drastic measures in several democratic countries. I think it says something about our trust in medical solutions. Today, we expect to be able to develop medicines and vaccines against different diseases in a way we didn't in the past.

The rush to develop gene-tampering COVID-19 vaccines is also accelerating the conjoined-twins fusion of pharma and biotech. The lucrative [biopharma sector](#) is now the fastest-growing segment of the global drug industry, currently representing 20% of the worldwide market and displaying an annual growth rate that is more than double that of conventional pharma. And COVID-19 vaccines are helping rescue some biopharma companies' shaky bottom lines. In 2017, for example, Moderna was [struggling](#) to "keep afloat its brash promise to reinvent medicine" after an experimental therapy that it was counting on proved too unsafe to test in humans. Fast forward to 2020, when "bad news about the coronavirus is [good news](#) for Moderna stock." Other biopharma companies formerly on the skids are likewise poised to make [record profits](#) from COVID-19.

As biopharma pursues its unfettered, medical-ethics-be-damned race toward a COVID-19 pot of gold, the public needs to take a critical look at the industry's disincentives for safety and also take a firm stand against the horrifying prospect of coronavirus vaccine mandates. Otherwise, genetically engineered COVID-19 vaccines are likely to start permanently altering genes, triggering autoimmunity and serving as the

catalyst for [other vaccine injuries or deaths](#), and—unhampered by any [legal liability](#)—none of the commercial or government actors responsible will likely care.

Twenty experimental COVID-19 nucleic acid vaccines (as of April 23, 2020)

Entities Involved	Technologies	Status and Funding
Applied DNA Sciences (NY); Takis Biotech (Italy)	PCR-produced LinearDNA	Preclinical animal testing underway since April in mice (five versions).
Arcturus Therapeutics (CA); Duke-National University of Singapore Medical School	Self-replicating mRNA (STARR platform); nanoparticle non-viral delivery system (LUNAR)	No timeline provided for human trials. \$10 million in funding from Singapore Economic Development Board.
BIOCAD (Russia)	mRNA (liposome-encapsulated)	Animal testing underway.
BioNet Asia (Thai-French); Thai National Control Lab	DNA	Entering preclinical studies. MOU signed with Thai Ministry of Health.
BioNTech (Germany); Fosun Pharma; Pfizer	Four mRNA candidates (modRNA, uRNA, self-amplifying mRNA)	Phase 1/2 trials (200 participants ages 18-55) approved in Germany for “BNT162”; U.S. approval expected.
Centro Nacional Biotecnología (Spain)	RNA (replicating defective SARS-CoV-2 derived RNAs)	4.5 million euros in funding from Spanish government.
China CDC; Tongji University; Stermina	mRNA	Animal testing underway, clinical trials anticipated.
CureVac (MA and Germany); Acuitas Therapeutics; Arcturus Therapeutics	mRNA	Phase I clinical trial in early summer. CEPI funding for vaccine platform (\$8.3 million) and RNA printer (\$34 million). European Commission funding for expanded manufacturing (\$88 million).
Russia State Research Center of Virology and Biotechnology	mRNA	No information available.
Fudan University; Shanghai JiaoTong University; RNACure Biopharma	mRNA (LNP-encapsulated cocktail encoding VLP; LNP-encapsulated encoding RBD)	Comparing different mRNA strategies.
Immunomics Therapeutics (MD); EpiVax (RI); PharmaJet (CO)	DNA (UNITE platform); PharmaJet needle-free injection delivery system	Building on PharmaJet’s active collaboration with BARDA and Department of Defense.
Imperial College London	Self-amplifying RNA	Testing in mice underway. Clinical trials in June 2020. Funding secured from UK Secretary of State for Health.
Inovio Pharmaceuticals (PA); International Vaccine Institute; Korea National Institute of Health	DNA with electroporation	Phase 1 clinical trial of “INO-4800” launched April 6 in the U.S. (Philadelphia, Kansas City) with up to 40 volunteers. Parallel Phase 1 trial in South Korea. Up to \$65 million in CEPI funding. Additional funding from Bill & Melinda Gates Foundation.
Karolinska Institute (Sweden); Cobra Biologics (UK)	DNA with electroporation	Longer-term focus on a vaccine to protect against multiple coronaviruses.
Moderna, Inc. (MA); NIAID; Lonza Group (Switzerland)	mRNA (LNP-encapsulated mRNA)	Phase 1 clinical trial of “mRNA-1273” with 45 participants (ages 18-55): Seattle (Kaiser); Atlanta (Emory); Bethesda (NIH). Expanded to include adults aged 56-plus. Application submitted to FDA (April 27) for Phase 2 studies. \$483 million in funding from BARDA, plus CEPI funding.
Osaka University (Japan); Angen Inc.; Takara Bio; Daicel	DNA	Collaboration announced on March 5. Animal testing to begin soon.
University of Tokyo; Daiichi-Sankyo	mRNA (LNP-encapsulated mRNA)	No information available.
University of Waterloo (Canada)	DNA; nanomedicine; nasal spray delivery	Design underway. Funding from the Natural Sciences and Engineering Research Council of Canada.
Zydus Cadila (India)	DNA	No information available.

Key: BARDA: Biomedical Advanced Research and Development Authority (part of HHS); CEPI: Coalition for Epidemic Preparedness Innovations; FDA: U.S. Food and Drug Administration; GSK: GlaxoSmithKline; HHS: Department of Health and Human Services; MOU: Memorandum of understanding; NIAID: National Institute of Allergy and Infectious Diseases

